Underwriting AgreementUnderwriting Agreement • July 16th, 2020 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • New York
Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), proposes, subject to the terms and conditions stated in this underwriting agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule II hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as representatives (the “Representatives”), and that certain shareholder of the Company named in Schedule I hereto (the “Selling Shareholder”) proposes, subject to the terms and conditions stated in this Agreement, to sell to the several Underwriters, an aggregate of 8,000,000 shares of the common stock, par value $0.0001 per share (“Stock”), of which 6,000,000 shares of Stock are to be issued and sold by the Company and 2,000,000 shares of Stock are to be sold by the Selling Shareholder. The Company also proposes to issue and sell to the several Underwriters, at the election of the Underwriters, up to 1,200,000 ad
